JP2001523272A - マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤 - Google Patents
マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤Info
- Publication number
- JP2001523272A JP2001523272A JP51106299A JP51106299A JP2001523272A JP 2001523272 A JP2001523272 A JP 2001523272A JP 51106299 A JP51106299 A JP 51106299A JP 51106299 A JP51106299 A JP 51106299A JP 2001523272 A JP2001523272 A JP 2001523272A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- hydroxyformamide
- ethyl
- biphenyl
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract description 10
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract description 10
- 239000003112 inhibitor Substances 0.000 title description 5
- 230000002441 reversible effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 270
- 238000000034 method Methods 0.000 claims abstract description 130
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- -1 And (10) to (17) Chemical group 0.000 claims description 368
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 297
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 266
- 125000004432 carbon atom Chemical group C* 0.000 claims description 151
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 94
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 68
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 63
- 125000002947 alkylene group Chemical group 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 34
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 24
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims description 23
- 150000001721 carbon Chemical group 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 17
- 235000010290 biphenyl Nutrition 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims description 10
- 125000001589 carboacyl group Chemical group 0.000 claims description 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 8
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 7
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 239000004305 biphenyl Substances 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- XJIQVSMHQQCBEO-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(3-ethyl-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(CC)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 XJIQVSMHQQCBEO-UHFFFAOYSA-N 0.000 claims description 6
- YJNJISQXBXDEOV-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenyl]sulfonyl-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 YJNJISQXBXDEOV-UHFFFAOYSA-N 0.000 claims description 6
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 claims description 5
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 claims description 5
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- MSWYFTOHLLVIHA-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(1,3-dioxoisoindol-2-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 MSWYFTOHLLVIHA-UHFFFAOYSA-N 0.000 claims description 5
- RNHVOKXLHUNLLK-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CCC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 RNHVOKXLHUNLLK-UHFFFAOYSA-N 0.000 claims description 5
- LMPYEOITPRIIBO-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-6-(4-methyl-2-oxochromen-6-yl)oxyhexan-2-yl]-n-hydroxyformamide Chemical compound C=1C=2C(C)=CC(=O)OC=2C=CC=1OCCCCC(N(O)C=O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 LMPYEOITPRIIBO-UHFFFAOYSA-N 0.000 claims description 5
- FQLYLGDLLIEWGU-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCC(C)N(O)C=O)=CC=C1C1=CC=C(C#N)C=C1 FQLYLGDLLIEWGU-UHFFFAOYSA-N 0.000 claims description 5
- XZQSZIUWGKWDSQ-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-methoxyphenyl)phenyl]sulfonylpropan-2-yl]formamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(S(=O)(=O)CC(C)N(O)C=O)C=C1 XZQSZIUWGKWDSQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- DDIVNBNVNDEYEX-UHFFFAOYSA-N n-[1-(2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound O=C1CNC(=O)N1CC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=C(OC(F)(F)F)C=C1 DDIVNBNVNDEYEX-UHFFFAOYSA-N 0.000 claims description 4
- TUACOILKNZYSRO-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-(4-methylsulfonylphenyl)phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=C1 TUACOILKNZYSRO-UHFFFAOYSA-N 0.000 claims description 4
- HWDWIUOVTBRTEG-UHFFFAOYSA-N n-[1-[2-(4-chlorophenoxy)phenyl]sulfonyl-4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)butan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CCC(N(O)C=O)CS(=O)(=O)C1=CC=CC=C1OC1=CC=C(Cl)C=C1 HWDWIUOVTBRTEG-UHFFFAOYSA-N 0.000 claims description 4
- QQFFLMZJIVBXJZ-UHFFFAOYSA-N n-[1-[4-(3-cyanophenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=C(C=CC=2)C#N)C=C1 QQFFLMZJIVBXJZ-UHFFFAOYSA-N 0.000 claims description 4
- MIXVCULNWAELJE-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 MIXVCULNWAELJE-UHFFFAOYSA-N 0.000 claims description 4
- BAFOVWYVJUJIOU-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-methylpentan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCC(C(C)CC)N(O)C=O)=CC=C1C1=CC=C(C#N)C=C1 BAFOVWYVJUJIOU-UHFFFAOYSA-N 0.000 claims description 4
- HVVHLZYFESCXRG-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-5-(4-methyl-2-oxochromen-7-yl)oxypentan-2-yl]-n-hydroxyformamide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1OCCCC(N(O)C=O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 HVVHLZYFESCXRG-UHFFFAOYSA-N 0.000 claims description 4
- KQQXPBSVPLBPNS-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenyl]sulfonyl-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 KQQXPBSVPLBPNS-UHFFFAOYSA-N 0.000 claims description 4
- XYOQWWNKGGMZPD-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenoxy]hexan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCC(CCCC)N(O)C=O)=CC=C1C1=CC=CC(CC#N)=C1 XYOQWWNKGGMZPD-UHFFFAOYSA-N 0.000 claims description 4
- BTBPCMSPHATHAZ-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenyl]sulfonyl-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=C(CC#N)C=CC=2)C=C1 BTBPCMSPHATHAZ-UHFFFAOYSA-N 0.000 claims description 4
- ZNNXZLSZATUSQW-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenyl]sulfonyl-4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)butan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CCC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=C(CC#N)C=CC=2)C=C1 ZNNXZLSZATUSQW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 4
- QRYTXFUBAZNNBP-UHFFFAOYSA-N 1-ethoxy-4-phenylbenzene Chemical compound C1=CC(OCC)=CC=C1C1=CC=CC=C1 QRYTXFUBAZNNBP-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- POAAMXKPZQWPLA-UHFFFAOYSA-N n-[1,3-bis[4-(4-cyanophenyl)phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound C=1C=C(C=2C=CC(=CC=2)C#N)C=CC=1OCC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 POAAMXKPZQWPLA-UHFFFAOYSA-N 0.000 claims description 3
- PCARMIDLDKHAKO-UHFFFAOYSA-N n-[1-[2-(4-cyanophenoxy)phenyl]sulfonyl-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=CC=C1OC1=CC=C(C#N)C=C1 PCARMIDLDKHAKO-UHFFFAOYSA-N 0.000 claims description 3
- QJZSCTMUARGKHY-UHFFFAOYSA-N n-[1-[4-(3-cyanophenyl)phenoxy]-3-(2,5-dioxopyrrolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1CCC(=O)N1CC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=CC(C#N)=C1 QJZSCTMUARGKHY-UHFFFAOYSA-N 0.000 claims description 3
- QXXFWTHPPBRNBY-UHFFFAOYSA-N n-[1-[4-(3-cyanophenyl)phenoxy]-3-[methyl-(4-methylphenyl)sulfonylamino]propan-2-yl]-n-hydroxyformamide Chemical compound C=1C=C(C)C=CC=1S(=O)(=O)N(C)CC(N(O)C=O)COC(C=C1)=CC=C1C1=CC=CC(C#N)=C1 QXXFWTHPPBRNBY-UHFFFAOYSA-N 0.000 claims description 3
- XGWRFBLPLXGEOJ-UHFFFAOYSA-N n-[1-[4-(4-butoxyphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCCCC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)N(C)C1=O XGWRFBLPLXGEOJ-UHFFFAOYSA-N 0.000 claims description 3
- NATAXQWJZDVABL-UHFFFAOYSA-N n-[1-[4-(4-butoxyphenyl)phenyl]sulfonyl-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCCCC)=CC=C1C1=CC=C(S(=O)(=O)CC(CN2C(C(C)(C)NC2=O)=O)N(O)C=O)C=C1 NATAXQWJZDVABL-UHFFFAOYSA-N 0.000 claims description 3
- XRTSSYISSDHDEO-UHFFFAOYSA-N n-[1-[4-(4-chlorophenoxy)phenyl]sulfonylpropan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(S(=O)(=O)CC(C)N(O)C=O)=CC=C1OC1=CC=C(Cl)C=C1 XRTSSYISSDHDEO-UHFFFAOYSA-N 0.000 claims description 3
- RLYMHSAWZIFELB-UHFFFAOYSA-N n-[1-[4-(4-chlorophenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 RLYMHSAWZIFELB-UHFFFAOYSA-N 0.000 claims description 3
- ULESHZVJAOPKFU-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(3,5,5-trimethyl-2,4-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound CC1(C)C(=O)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 ULESHZVJAOPKFU-UHFFFAOYSA-N 0.000 claims description 3
- YGUKHRAGYHDVCC-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-4-methylpentan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCC(CC(C)C)N(O)C=O)=CC=C1C1=CC=C(C#N)C=C1 YGUKHRAGYHDVCC-UHFFFAOYSA-N 0.000 claims description 3
- CLMLZOGCBKCTRX-UHFFFAOYSA-N n-[1-[4-(4-fluorophenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(F)=CC=2)C=C1 CLMLZOGCBKCTRX-UHFFFAOYSA-N 0.000 claims description 3
- WCKLNALJHKEBOA-UHFFFAOYSA-N n-[1-[4-(furan-2-yl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2OC=CC=2)C=C1 WCKLNALJHKEBOA-UHFFFAOYSA-N 0.000 claims description 3
- IGLNVBIFWLJSLW-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenoxy]-3-(3,5,5-trimethyl-2,4-dioxoimidazolidin-1-yl)butan-2-yl]-n-hydroxyformamide Chemical compound O=C1N(C)C(=O)C(C)(C)N1C(C)C(N(O)C=O)COC(C=C1)=CC=C1C1=CC=CC(CC#N)=C1 IGLNVBIFWLJSLW-UHFFFAOYSA-N 0.000 claims description 3
- MJDJFIONJBJENE-UHFFFAOYSA-N n-[2-[4-(4-cyanophenyl)phenoxy]ethyl]-n-hydroxyformamide Chemical compound C1=CC(OCCN(O)C=O)=CC=C1C1=CC=C(C#N)C=C1 MJDJFIONJBJENE-UHFFFAOYSA-N 0.000 claims description 3
- JVVKABKXJZQUKB-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-methoxyphenyl)phenyl]sulfonylbutan-2-yl]formamide Chemical compound C1=CC(S(=O)(=O)CC(CC)N(O)C=O)=CC=C1C1=CC=C(OC)C=C1 JVVKABKXJZQUKB-UHFFFAOYSA-N 0.000 claims description 3
- KLPXBGLTDZNLHF-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-methylphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(C)=CC=2)C=C1 KLPXBGLTDZNLHF-UHFFFAOYSA-N 0.000 claims description 3
- BOKCOLBSYBKUBS-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-methylsulfonylphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=C1 BOKCOLBSYBKUBS-UHFFFAOYSA-N 0.000 claims description 3
- AEVRXLMMFOVCSF-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-phenylpiperidin-1-yl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(N2CCC(CC2)C=2C=CC=CC=2)C=C1 AEVRXLMMFOVCSF-UHFFFAOYSA-N 0.000 claims description 3
- 125000005893 naphthalimidyl group Chemical group 0.000 claims description 3
- 125000005545 phthalimidyl group Chemical group 0.000 claims description 3
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- IKUMWXFHSNMROL-UHFFFAOYSA-N 3-thiomorpholin-3-ylsulfonylthiomorpholine Chemical compound C1SCCNC1S(=O)(=O)C1CSCCN1 IKUMWXFHSNMROL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- LRBVCZWIGFVWJC-UHFFFAOYSA-N n-[1-[4-(4-butoxyphenyl)phenoxy]-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCCCC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)NC1=O LRBVCZWIGFVWJC-UHFFFAOYSA-N 0.000 claims description 2
- AWGNXPZLIKSBIH-UHFFFAOYSA-N n-[1-[4-(4-chlorophenyl)phenyl]sulfonylpropan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(S(=O)(=O)CC(C)N(O)C=O)=CC=C1C1=CC=C(Cl)C=C1 AWGNXPZLIKSBIH-UHFFFAOYSA-N 0.000 claims description 2
- FAKNSYBPLCTEOM-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-5-(4-methyl-2-oxochromen-6-yl)oxypentan-2-yl]-n-hydroxyformamide Chemical compound C=1C=2C(C)=CC(=O)OC=2C=CC=1OCCCC(N(O)C=O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 FAKNSYBPLCTEOM-UHFFFAOYSA-N 0.000 claims description 2
- CYZIGKAKVFFVHK-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-6-(4-methyl-2-oxochromen-7-yl)oxyhexan-2-yl]-n-hydroxyformamide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1OCCCCC(N(O)C=O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 CYZIGKAKVFFVHK-UHFFFAOYSA-N 0.000 claims description 2
- YDLMSZYANACZSD-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]hexan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCC(CCCC)N(O)C=O)=CC=C1C1=CC=C(C#N)C=C1 YDLMSZYANACZSD-UHFFFAOYSA-N 0.000 claims description 2
- MNJMYVINLUNQLL-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenyl]sulfonyl-3-(3-methyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1N(C)CC(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 MNJMYVINLUNQLL-UHFFFAOYSA-N 0.000 claims description 2
- TXLDYMKLAXEZDM-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=C(CC#N)C=CC=2)C=C1 TXLDYMKLAXEZDM-UHFFFAOYSA-N 0.000 claims description 2
- ZEECGMPIRIXCDS-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenoxy]-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=C(CC#N)C=CC=2)C=C1 ZEECGMPIRIXCDS-UHFFFAOYSA-N 0.000 claims description 2
- BNHLWCDTAJCBFL-UHFFFAOYSA-N n-hydroxy-n-[1-(4-pyridin-4-ylphenoxy)-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CN=CC=2)C=C1 BNHLWCDTAJCBFL-UHFFFAOYSA-N 0.000 claims description 2
- CUEYMQQJCZDCNZ-UHFFFAOYSA-N n-hydroxy-n-[1-(4-thiophen-3-ylphenoxy)-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C2=CSC=C2)C=C1 CUEYMQQJCZDCNZ-UHFFFAOYSA-N 0.000 claims description 2
- UHDOFMGCOILUFG-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(2-methylphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C(=CC=CC=2)C)C=C1 UHDOFMGCOILUFG-UHFFFAOYSA-N 0.000 claims description 2
- VFTMPAUKSSAOIO-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-sulfamoylphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)S(N)(=O)=O)C=C1 VFTMPAUKSSAOIO-UHFFFAOYSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- KILYFHYTMDFZTB-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenyl]sulfonylpropan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)C=C1 KILYFHYTMDFZTB-UHFFFAOYSA-N 0.000 claims 2
- RLIATYHSAHYWGM-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1CC(C)(C)CC(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 RLIATYHSAHYWGM-UHFFFAOYSA-N 0.000 claims 2
- VGAPCTSBAGOGFW-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-methylsulfanylphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound C1=CC(SC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)N(C)C1=O VGAPCTSBAGOGFW-UHFFFAOYSA-N 0.000 claims 2
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- SAAGYSZSTMZQJX-UHFFFAOYSA-N n-[1-[4-(4-butylphenyl)phenoxy]-3-(3-methyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(CCCC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)N(C)CC1=O SAAGYSZSTMZQJX-UHFFFAOYSA-N 0.000 claims 1
- CXHZULGXLODPRR-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(3-methyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1N(C)CC(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 CXHZULGXLODPRR-UHFFFAOYSA-N 0.000 claims 1
- ZZXQNPUBOBVRJZ-UHFFFAOYSA-N n-[1-[4-[3-(cyanomethyl)phenyl]phenoxy]-4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)butan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CCC(N(O)C=O)COC1=CC=C(C=2C=C(CC#N)C=CC=2)C=C1 ZZXQNPUBOBVRJZ-UHFFFAOYSA-N 0.000 claims 1
- CGCAAEYUYRARCO-UHFFFAOYSA-N n-[4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-1-[4-[4-(trifluoromethoxy)phenyl]phenoxy]butan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CCC(N(O)C=O)COC1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)C=C1 CGCAAEYUYRARCO-UHFFFAOYSA-N 0.000 claims 1
- NOJIQYLBNRETQN-UHFFFAOYSA-N n-hydroxy-n-[1-[4-(4-methoxyphenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound C1=CC(OC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)N(C)C1=O NOJIQYLBNRETQN-UHFFFAOYSA-N 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract description 3
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 459
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 163
- 235000019439 ethyl acetate Nutrition 0.000 description 153
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 151
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 128
- 238000005481 NMR spectroscopy Methods 0.000 description 116
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 88
- 239000000243 solution Substances 0.000 description 84
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 76
- 238000004458 analytical method Methods 0.000 description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 70
- 239000000741 silica gel Substances 0.000 description 66
- 229910002027 silica gel Inorganic materials 0.000 description 66
- 239000011734 sodium Substances 0.000 description 65
- 239000007787 solid Substances 0.000 description 61
- 229910001868 water Inorganic materials 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- 239000012267 brine Substances 0.000 description 56
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 239000012044 organic layer Substances 0.000 description 46
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 34
- 238000003756 stirring Methods 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 29
- 238000000746 purification Methods 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 238000002844 melting Methods 0.000 description 25
- 230000008018 melting Effects 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- 239000000284 extract Substances 0.000 description 23
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical group OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000005259 measurement Methods 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 235000008504 concentrate Nutrition 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 235000011181 potassium carbonates Nutrition 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- ZRMIETZFPZGBEB-UHFFFAOYSA-N 4-(4-hydroxyphenyl)benzonitrile Chemical compound C1=CC(O)=CC=C1C1=CC=C(C#N)C=C1 ZRMIETZFPZGBEB-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 239000007795 chemical reaction product Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 8
- 229940091173 hydantoin Drugs 0.000 description 8
- 238000005192 partition Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- MWWKMFTXNBHVJT-UHFFFAOYSA-N 4-(4-butoxyphenyl)phenol Chemical group C1=CC(OCCCC)=CC=C1C1=CC=C(O)C=C1 MWWKMFTXNBHVJT-UHFFFAOYSA-N 0.000 description 7
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000002923 oximes Chemical class 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- ZNYIPTYJBRGSSL-UHFFFAOYSA-N 1,5,5-trimethylimidazolidine-2,4-dione Chemical compound CN1C(=O)NC(=O)C1(C)C ZNYIPTYJBRGSSL-UHFFFAOYSA-N 0.000 description 6
- SAVUMZAYQJUCOL-UHFFFAOYSA-N 4-(4-ethoxyphenyl)phenol Chemical group C1=CC(OCC)=CC=C1C1=CC=C(O)C=C1 SAVUMZAYQJUCOL-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- UIZVMOZAXAMASY-UHFFFAOYSA-N hex-5-en-1-ol Chemical compound OCCCCC=C UIZVMOZAXAMASY-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QUPFQMXWFNJUNJ-UHFFFAOYSA-N (4-butoxyphenyl)boronic acid Chemical compound CCCCOC1=CC=C(B(O)O)C=C1 QUPFQMXWFNJUNJ-UHFFFAOYSA-N 0.000 description 5
- BPMBNLJJRKCCRT-UHFFFAOYSA-N 4-phenylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CC=C1 BPMBNLJJRKCCRT-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- DQDWATOXYCARFV-UHFFFAOYSA-M magnesium;2-methanidylpropane;bromide Chemical compound [Mg+2].[Br-].CC(C)[CH2-] DQDWATOXYCARFV-UHFFFAOYSA-M 0.000 description 5
- 150000003457 sulfones Chemical class 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- 238000001665 trituration Methods 0.000 description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 4
- FTBCOQFMQSTCQQ-UHFFFAOYSA-N 4-bromobenzenethiol Chemical compound SC1=CC=C(Br)C=C1 FTBCOQFMQSTCQQ-UHFFFAOYSA-N 0.000 description 4
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- YIROYDNZEPTFOL-UHFFFAOYSA-N 5,5-Dimethylhydantoin Chemical compound CC1(C)NC(=O)NC1=O YIROYDNZEPTFOL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- 229910052776 Thorium Inorganic materials 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000022244 formylation Effects 0.000 description 3
- 238000006170 formylation reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- LWLPYZUDBNFNAH-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CCC[CH2-] LWLPYZUDBNFNAH-UHFFFAOYSA-M 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- VRDVYZAEYHXMTJ-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-phenoxypropan-2-yl]-n-hydroxyformamide Chemical compound C=1C=C(C=2C=CC(=CC=2)C#N)C=CC=1OCC(N(C=O)O)COC1=CC=CC=C1 VRDVYZAEYHXMTJ-UHFFFAOYSA-N 0.000 description 3
- ZOQRCAUTYNYRRI-UHFFFAOYSA-N n-[2-[4-(4-cyanophenyl)phenoxy]ethyl]-n-hydroxyacetamide Chemical compound C1=CC(OCCN(O)C(=O)C)=CC=C1C1=CC=C(C#N)C=C1 ZOQRCAUTYNYRRI-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- NNLJLPZWDPOEAW-UHFFFAOYSA-N potassium;pyrrolidine-2,5-dione Chemical compound [K].O=C1CCC(=O)N1 NNLJLPZWDPOEAW-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QNYBOILAKBSWFG-SNVBAGLBSA-N (2s)-2-(phenylmethoxymethyl)oxirane Chemical compound C([C@H]1OC1)OCC1=CC=CC=C1 QNYBOILAKBSWFG-SNVBAGLBSA-N 0.000 description 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
- CMHPUBKZZPSUIQ-UHFFFAOYSA-N 1,3-benzodioxol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OCOC2=C1 CMHPUBKZZPSUIQ-UHFFFAOYSA-N 0.000 description 2
- ANJDRZRBNJJLRW-UHFFFAOYSA-N 1-benzyl-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)C(C)(C)N1CC1=CC=CC=C1 ANJDRZRBNJJLRW-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QZWIXLPWMGHDDD-UHFFFAOYSA-N 3-methyl-1h-pyridazin-6-one Chemical compound CC1=CC=C(O)N=N1 QZWIXLPWMGHDDD-UHFFFAOYSA-N 0.000 description 2
- AFXSLKKTDUYDIR-UHFFFAOYSA-N 4-(4-chlorophenoxy)benzenethiol Chemical compound C1=CC(S)=CC=C1OC1=CC=C(Cl)C=C1 AFXSLKKTDUYDIR-UHFFFAOYSA-N 0.000 description 2
- CORJIEYQXMZUIW-UHFFFAOYSA-N 4-(4-methoxyphenyl)phenol Chemical compound C1=CC(OC)=CC=C1C1=CC=C(O)C=C1 CORJIEYQXMZUIW-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- IRUHWRSITUYICV-UHFFFAOYSA-N 6-hydroxy-4-methylchromen-2-one Chemical compound C1=CC(O)=CC2=C1OC(=O)C=C2C IRUHWRSITUYICV-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Chemical compound CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical group C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 2
- RVIQSSNDHKQZHH-UHFFFAOYSA-N carbonyl diiodide Chemical compound IC(I)=O RVIQSSNDHKQZHH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- FQCGONNCIXUVIT-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-(4-pentoxyphenyl)phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCCCCC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)NC1=O FQCGONNCIXUVIT-UHFFFAOYSA-N 0.000 description 2
- AIERVSLSBDPXAI-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethyl)phenyl]phenyl]sulfanylpropan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)CSC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 AIERVSLSBDPXAI-UHFFFAOYSA-N 0.000 description 2
- XRADERRLWUPWAX-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-[4,4-dimethyl-2,5-dioxo-3-(pyridin-3-ylmethyl)imidazolidin-1-yl]propan-2-yl]-n-hydroxyformamide Chemical compound O=C1N(CC(COC=2C=CC(=CC=2)C=2C=CC(=CC=2)C#N)N(O)C=O)C(=O)C(C)(C)N1CC1=CC=CN=C1 XRADERRLWUPWAX-UHFFFAOYSA-N 0.000 description 2
- VDUIPQNXOQMTBF-UHFFFAOYSA-N n-ethylhydroxylamine Chemical compound CCNO VDUIPQNXOQMTBF-UHFFFAOYSA-N 0.000 description 2
- JORWZOVHRIEXHF-UHFFFAOYSA-N n-hydroxy-n-[1-(3-methyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]formamide Chemical compound O=C1N(C)CC(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)C=C1 JORWZOVHRIEXHF-UHFFFAOYSA-N 0.000 description 2
- MQQVEFUFSUQVBA-UHFFFAOYSA-N n-hydroxy-n-methylpropanamide Chemical compound CCC(=O)N(C)O MQQVEFUFSUQVBA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- BUQTYVUSGLJSKS-UHFFFAOYSA-N tert-butyl n-hydroxy-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(O)C(=O)OC(C)(C)C BUQTYVUSGLJSKS-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QNYBOILAKBSWFG-JTQLQIEISA-N (2r)-2-(phenylmethoxymethyl)oxirane Chemical compound C([C@@H]1OC1)OCC1=CC=CC=C1 QNYBOILAKBSWFG-JTQLQIEISA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HWKPTBHJWBSOOP-UHFFFAOYSA-N (4-bromophenoxy)-trimethylsilane Chemical compound C[Si](C)(C)OC1=CC=C(Br)C=C1 HWKPTBHJWBSOOP-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- WSIAUAAWNSTTGT-UHFFFAOYSA-N 1,1'-biphenyl;methylsulfonylmethane Chemical group CS(C)(=O)=O.C1=CC=CC=C1C1=CC=CC=C1 WSIAUAAWNSTTGT-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WEZAHEDFMMQMTD-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=C(C(F)(F)F)C=C1 WEZAHEDFMMQMTD-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ZRGXEUQNKDHIKA-UHFFFAOYSA-N 1-[4-(4-methoxyphenyl)phenyl]sulfonyl-N-phenylmethoxypropan-2-amine Chemical compound C1=CC(OC)=CC=C1C1=CC=C(S(=O)(=O)CC(C)NOCC=2C=CC=CC=2)C=C1 ZRGXEUQNKDHIKA-UHFFFAOYSA-N 0.000 description 1
- RIAOYLQTFIRFAJ-UHFFFAOYSA-N 1-[[4-[4-[2-(trifluoromethoxy)phenyl]phenoxy]phenyl]methoxy]propan-2-ol Chemical compound C1=CC(COCC(O)C)=CC=C1OC1=CC=C(C=2C(=CC=CC=2)OC(F)(F)F)C=C1 RIAOYLQTFIRFAJ-UHFFFAOYSA-N 0.000 description 1
- HFZNANUAQMQUME-UHFFFAOYSA-N 1-benzyl-3-[(4-methoxyphenyl)methyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C)(C)N(CC=2C=CC=CC=2)C1=O HFZNANUAQMQUME-UHFFFAOYSA-N 0.000 description 1
- IXVOFDJFLUCPRW-UHFFFAOYSA-N 1-bromo-1-phenoxypropan-2-one Chemical compound CC(=O)C(Br)OC1=CC=CC=C1 IXVOFDJFLUCPRW-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical group CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- YEUYZNNBXLMFCW-UHFFFAOYSA-N 1-bromo-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(Br)C=C1 YEUYZNNBXLMFCW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- GSEYCCYLXSVYNB-UHFFFAOYSA-N 1-ethyl-3-[(4-methoxyphenyl)methyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)N(CC)C(=O)N1CC1=CC=C(OC)C=C1 GSEYCCYLXSVYNB-UHFFFAOYSA-N 0.000 description 1
- JADALHRUMHUJBX-UHFFFAOYSA-N 1-ethyl-5,5-dimethylimidazolidine-2,4-dione Chemical compound CCN1C(=O)NC(=O)C1(C)C JADALHRUMHUJBX-UHFFFAOYSA-N 0.000 description 1
- DPJHZJGAGIWXTD-UHFFFAOYSA-N 1-fluoro-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(F)C=C1 DPJHZJGAGIWXTD-UHFFFAOYSA-N 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- JXHWSYHNRWPORQ-UHFFFAOYSA-N 1-nonoxypropan-2-ol Chemical compound CCCCCCCCCOCC(C)O JXHWSYHNRWPORQ-UHFFFAOYSA-N 0.000 description 1
- XREBEJBUPRGGTB-UHFFFAOYSA-N 1-phenylsulfanylpropan-2-one Chemical compound CC(=O)CSC1=CC=CC=C1 XREBEJBUPRGGTB-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- VEBHAMMTQRXOJT-UHFFFAOYSA-N 2-(2-methoxyphenyl)phenol Chemical compound COC1=CC=CC=C1C1=CC=CC=C1O VEBHAMMTQRXOJT-UHFFFAOYSA-N 0.000 description 1
- WVYPDPJNPRIPPW-UHFFFAOYSA-N 2-(2-phenylphenyl)acetonitrile Chemical group N#CCC1=CC=CC=C1C1=CC=CC=C1 WVYPDPJNPRIPPW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- YUQUNWNSQDULTI-UHFFFAOYSA-N 2-bromobenzenethiol Chemical compound SC1=CC=CC=C1Br YUQUNWNSQDULTI-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- XHRCFGDFESIFRG-UHFFFAOYSA-N 2-chloro-n-ethyl-n-[(2-methylphenyl)methyl]ethanamine Chemical compound ClCCN(CC)CC1=CC=CC=C1C XHRCFGDFESIFRG-UHFFFAOYSA-N 0.000 description 1
- GAAOKTBHSXYRNH-UHFFFAOYSA-N 2-chloro-n-ethyl-n-[(2-methylphenyl)methyl]ethanamine;hydrochloride Chemical compound [Cl-].ClCC[NH+](CC)CC1=CC=CC=C1C GAAOKTBHSXYRNH-UHFFFAOYSA-N 0.000 description 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- WOFSHNPWDNCXRL-UHFFFAOYSA-N 2-methylsulfonyl-6-prop-2-enylaniline Chemical compound CS(=O)(=O)C=1C(=C(C=CC=1)CC=C)N WOFSHNPWDNCXRL-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- GAPVBMQBWAUBHC-UHFFFAOYSA-N 2-oxopropanoyl 2-oxopropanoate Chemical compound CC(=O)C(=O)OC(=O)C(C)=O GAPVBMQBWAUBHC-UHFFFAOYSA-N 0.000 description 1
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NFNOAHXEQXMCGT-UHFFFAOYSA-N 2-phenylmethoxyacetaldehyde Chemical compound O=CCOCC1=CC=CC=C1 NFNOAHXEQXMCGT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SKCQKTIUCVINNH-UHFFFAOYSA-N 3-(3-bromo-2-oxopropyl)-1,5,5-trimethylimidazolidine-2,4-dione Chemical compound CN1C(=O)N(CC(=O)CBr)C(=O)C1(C)C SKCQKTIUCVINNH-UHFFFAOYSA-N 0.000 description 1
- SGEXOHKSMUPKHG-UHFFFAOYSA-N 3-(3-bromo-2-oxopropyl)-1-methylimidazolidine-2,4-dione Chemical compound CN1CC(=O)N(CC(=O)CBr)C1=O SGEXOHKSMUPKHG-UHFFFAOYSA-N 0.000 description 1
- AASRSZNIUKHBLP-UHFFFAOYSA-N 3-(3-bromo-2-oxopropyl)imidazolidine-2,4-dione Chemical compound BrCC(=O)CN1C(=O)CNC1=O AASRSZNIUKHBLP-UHFFFAOYSA-N 0.000 description 1
- NWTWXRQJLSZJHW-UHFFFAOYSA-N 3-(3-iodo-2-oxopropyl)-1,5,5-trimethylimidazolidine-2,4-dione Chemical compound CN1C(=O)N(CC(=O)CI)C(=O)C1(C)C NWTWXRQJLSZJHW-UHFFFAOYSA-N 0.000 description 1
- HRXRXPBUGSJIDX-UHFFFAOYSA-N 3-(4-bromo-3-oxobutyl)-1,5,5-trimethylimidazolidine-2,4-dione Chemical compound CN1C(=O)N(CCC(=O)CBr)C(=O)C1(C)C HRXRXPBUGSJIDX-UHFFFAOYSA-N 0.000 description 1
- CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
- BUQJXRZRMCSIKR-UHFFFAOYSA-N 3-[3-[4-(4-butoxyphenyl)phenyl]sulfanyl-2-oxopropyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=CC(OCCCC)=CC=C1C(C=C1)=CC=C1SCC(=O)CN1C(=O)C(C)(C)NC1=O BUQJXRZRMCSIKR-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- BNBOUFHCTIFWHN-UHFFFAOYSA-N 3-bromobutan-2-one Chemical compound CC(Br)C(C)=O BNBOUFHCTIFWHN-UHFFFAOYSA-N 0.000 description 1
- JKHPOPCIKQQRPU-UHFFFAOYSA-N 3-chloro-2-(methoxymethoxy)prop-1-ene Chemical compound COCOC(=C)CCl JKHPOPCIKQQRPU-UHFFFAOYSA-N 0.000 description 1
- BGARPMGQRREXLN-UHFFFAOYSA-N 3-iodobenzonitrile Chemical compound IC1=CC=CC(C#N)=C1 BGARPMGQRREXLN-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- JIHMKTVYWHTJCD-UHFFFAOYSA-N 4-(3-chloro-4-fluorophenyl)phenol Chemical compound C1=CC(O)=CC=C1C1=CC=C(F)C(Cl)=C1 JIHMKTVYWHTJCD-UHFFFAOYSA-N 0.000 description 1
- OACHBIGUVRUHBJ-UHFFFAOYSA-N 4-(4-butylphenyl)phenol Chemical compound C1=CC(CCCC)=CC=C1C1=CC=C(O)C=C1 OACHBIGUVRUHBJ-UHFFFAOYSA-N 0.000 description 1
- QSJNKJGPJVOGPK-UHFFFAOYSA-N 4-(4-fluorophenyl)phenol Chemical compound C1=CC(O)=CC=C1C1=CC=C(F)C=C1 QSJNKJGPJVOGPK-UHFFFAOYSA-N 0.000 description 1
- FZZNGPBBVGRORC-UHFFFAOYSA-N 4-(4-sulfanylphenoxy)benzonitrile Chemical group C1=CC(S)=CC=C1OC1=CC=C(C#N)C=C1 FZZNGPBBVGRORC-UHFFFAOYSA-N 0.000 description 1
- ICVFJPSNAUMFCW-UHFFFAOYSA-N 4-Chloro-4'-biphenylol Chemical group C1=CC(O)=CC=C1C1=CC=C(Cl)C=C1 ICVFJPSNAUMFCW-UHFFFAOYSA-N 0.000 description 1
- KWPGDDALZCCTGH-UHFFFAOYSA-N 4-[4-(2-hydroxy-3-propan-2-ylsulfanylpropoxy)phenyl]benzonitrile Chemical compound C1=CC(OCC(O)CSC(C)C)=CC=C1C1=CC=C(C#N)C=C1 KWPGDDALZCCTGH-UHFFFAOYSA-N 0.000 description 1
- HBEXXUFCOPQQDU-UHFFFAOYSA-N 4-[4-(trifluoromethoxy)phenoxy]benzenethiol Chemical compound C1=CC(OC(F)(F)F)=CC=C1OC1=CC=C(S)C=C1 HBEXXUFCOPQQDU-UHFFFAOYSA-N 0.000 description 1
- LSYPVJRQPKWPEQ-UHFFFAOYSA-N 4-[4-[2-oxo-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propyl]sulfanylphenyl]benzonitrile Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(=O)CSC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 LSYPVJRQPKWPEQ-UHFFFAOYSA-N 0.000 description 1
- ZCMKTZSOEGSNMK-UHFFFAOYSA-N 4-[4-[3-(3-ethyl-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-oxopropoxy]phenyl]benzonitrile Chemical compound O=C1C(C)(C)N(CC)C(=O)N1CC(=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 ZCMKTZSOEGSNMK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- FPWNLURCHDRMHC-UHFFFAOYSA-N 4-chlorobiphenyl Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1 FPWNLURCHDRMHC-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- DANMQSWQAGVFKV-UHFFFAOYSA-N 4-pyridin-4-ylphenol Chemical group C1=CC(O)=CC=C1C1=CC=NC=C1 DANMQSWQAGVFKV-UHFFFAOYSA-N 0.000 description 1
- BXAVKNRWVKUTLY-UHFFFAOYSA-N 4-sulfanylphenol Chemical compound OC1=CC=C(S)C=C1 BXAVKNRWVKUTLY-UHFFFAOYSA-N 0.000 description 1
- YCPBQLGXVOSEDX-UHFFFAOYSA-N 5,5-dimethyl-3-propylimidazolidine-2,4-dione Chemical compound CCCN1C(=O)NC(C)(C)C1=O YCPBQLGXVOSEDX-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 241000114726 Acetes Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JHOLAQUEOKGZGK-UHFFFAOYSA-N C.OC1=CC=C(C=C1)C1=CC(=CC=C1)C#N Chemical compound C.OC1=CC=C(C=C1)C1=CC(=CC=C1)C#N JHOLAQUEOKGZGK-UHFFFAOYSA-N 0.000 description 1
- CAQWNKXTMBFBGI-UHFFFAOYSA-N C.[Na] Chemical compound C.[Na] CAQWNKXTMBFBGI-UHFFFAOYSA-N 0.000 description 1
- UYQGXLTUKXTBIU-UHFFFAOYSA-N CCCC[Sn]C#CC1=CC=CC=C1 Chemical compound CCCC[Sn]C#CC1=CC=CC=C1 UYQGXLTUKXTBIU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- ZYGSGSHCCMSFTL-UHFFFAOYSA-N N-[1-[4-(4-butoxyphenyl)phenyl]sulfanyl-3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-N-hydroxyformamide Chemical compound C1=CC(OCCCC)=CC=C1C(C=C1)=CC=C1SCC(N(O)C=O)CN1C(=O)C(C)(C)NC1=O ZYGSGSHCCMSFTL-UHFFFAOYSA-N 0.000 description 1
- JOXBLZSICQFDAH-UHFFFAOYSA-N N-[1-[4-(4-methoxyphenyl)phenyl]sulfonylpropan-2-yl]-N-phenylmethoxyformamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(S(=O)(=O)CC(C)N(OCC=2C=CC=CC=2)C=O)C=C1 JOXBLZSICQFDAH-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethylsuccinimide Chemical compound CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- JDHHFCKOCSYEJV-UHFFFAOYSA-M [Br-].CC1=CC=C(C[Mg+])C=C1 Chemical compound [Br-].CC1=CC=C(C[Mg+])C=C1 JDHHFCKOCSYEJV-UHFFFAOYSA-M 0.000 description 1
- FEXQMRQHXTYLDS-UHFFFAOYSA-M [Br-].FC1=CC=C(C[Mg+])C=C1 Chemical compound [Br-].FC1=CC=C(C[Mg+])C=C1 FEXQMRQHXTYLDS-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
- CWNKMHIETKEBCA-UHFFFAOYSA-N alpha-Ethylaminohexanophenone Chemical compound CCCCC(NCC)C(=O)C1=CC=CC=C1 CWNKMHIETKEBCA-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- SIIVGPQREKVCOP-UHFFFAOYSA-N but-1-en-1-ol Chemical compound CCC=CO SIIVGPQREKVCOP-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000012336 iodinating agent Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical group ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- YNLPNVNWHDKDMN-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CC[CH-]C YNLPNVNWHDKDMN-UHFFFAOYSA-M 0.000 description 1
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- KNPNGMXRGITFLE-UHFFFAOYSA-N methylperoxy(phenyl)borinic acid Chemical compound COOB(O)C1=CC=CC=C1 KNPNGMXRGITFLE-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- DCAVLRMJGJXYMZ-UHFFFAOYSA-N n-(3-bromophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(Br)=C1 DCAVLRMJGJXYMZ-UHFFFAOYSA-N 0.000 description 1
- DDXMPPFUPDTKNK-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-(4-propoxyphenyl)phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCCC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)NC1=O DDXMPPFUPDTKNK-UHFFFAOYSA-N 0.000 description 1
- ZLPOIHFXRODFHL-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(2-methoxyethoxy)phenyl]phenoxy]propan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OCCOC)=CC=C1C(C=C1)=CC=C1OCC(N(O)C=O)CN1C(=O)C(C)(C)NC1=O ZLPOIHFXRODFHL-UHFFFAOYSA-N 0.000 description 1
- BYBOLCACCXBYNF-UHFFFAOYSA-N n-[1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethyl)phenyl]phenyl]sulfonylpropan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)NC(=O)N1CC(N(O)C=O)CS(=O)(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 BYBOLCACCXBYNF-UHFFFAOYSA-N 0.000 description 1
- SZNWFKFEQOHKFC-UHFFFAOYSA-N n-[1-[4-(3-chloro-4-fluorophenyl)phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=C(Cl)C(F)=CC=2)C=C1 SZNWFKFEQOHKFC-UHFFFAOYSA-N 0.000 description 1
- SBVGWUXDJBPGDG-UHFFFAOYSA-N n-[1-[4-(4-chlorophenoxy)phenyl]sulfonyl-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)CS(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 SBVGWUXDJBPGDG-UHFFFAOYSA-N 0.000 description 1
- DXWAVUNOHWJUME-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(1,1,3-trioxo-1,2-benzothiazol-2-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C2=CC=CC=C2S(=O)(=O)N1CC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 DXWAVUNOHWJUME-UHFFFAOYSA-N 0.000 description 1
- JXKUSYFOHKHALF-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(2,5-dioxoimidazolidin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1CNC(=O)N1CC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 JXKUSYFOHKHALF-UHFFFAOYSA-N 0.000 description 1
- LAPCQFPRLGAHEW-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)propan-2-yl]-n-hydroxyformamide Chemical compound O=C1C(C)(C)OC(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 LAPCQFPRLGAHEW-UHFFFAOYSA-N 0.000 description 1
- AHWRSCRGJVHGKN-UHFFFAOYSA-N n-[1-[4-(4-cyanophenyl)phenoxy]-3-(6-oxopyridazin-1-yl)propan-2-yl]-n-hydroxyformamide Chemical compound N1=CC=CC(=O)N1CC(N(C=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 AHWRSCRGJVHGKN-UHFFFAOYSA-N 0.000 description 1
- BTCMWOQFIIODAT-UHFFFAOYSA-N n-[3-[4-(4-cyanophenyl)phenoxy]butan-2-yl]-n-hydroxyformamide Chemical compound C1=CC(OC(C)C(C)N(O)C=O)=CC=C1C1=CC=C(C#N)C=C1 BTCMWOQFIIODAT-UHFFFAOYSA-N 0.000 description 1
- SVFMOIINCMVSKB-UHFFFAOYSA-N n-ethyl-n-hydroxyformamide Chemical compound CCN(O)C=O SVFMOIINCMVSKB-UHFFFAOYSA-N 0.000 description 1
- SWYHJAFCOHHOEN-UHFFFAOYSA-N n-hydroxy-n-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propan-2-yl]formamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC(N(O)C=O)COC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 SWYHJAFCOHHOEN-UHFFFAOYSA-N 0.000 description 1
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical compound ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LHTVMBMETNGEAN-UHFFFAOYSA-N pent-1-en-1-ol Chemical compound CCCC=CO LHTVMBMETNGEAN-UHFFFAOYSA-N 0.000 description 1
- LQAVWYMTUMSFBE-UHFFFAOYSA-N pent-4-en-1-ol Chemical compound OCCCC=C LQAVWYMTUMSFBE-UHFFFAOYSA-N 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical group OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PYMPTRMDPJYTDF-UHFFFAOYSA-N tributyl(2-phenylethynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC1=CC=CC=C1 PYMPTRMDPJYTDF-UHFFFAOYSA-N 0.000 description 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
- C07C323/47—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Detergent Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式(I)の化合物、 または医薬的に許容できるそれらの塩もしくはプロドラッグであって、 Aが水素、 nがゼロ、 R1およびR3が (1)水素、および (2)炭素原子1個から6個のアルキル からなるグループから独立して選択され、 R2およびR4が (1)水素、 (2)炭素原子1個から6個のアルキル、 (3)炭素原子1個から6個のアルケニル、 (4)炭素原子1個から6個のアルキニル、 (5)アルコキシアルキル、 (6)アルキレンおよびアルキル基の炭素原子が独立して1個から6個であるア ルコキシカルボニルアルキル、 (7)炭素原子1個から6個のハロアルキル、 (8)アルキレン基の炭素原子が1個から6個であるヒドロキシアルキル、 (9)アルキレンの炭素原子が1個から6個であり、アルキルの炭素原子が1個 から6個である−(アルキレン)−S(O)p−アルキル、 (10)フェニル、 (11)アルキレンおよびアルキル基の炭素原子が独立して1個から6個である フェニルアルコキシアルキル、 (12)アルキレン基の炭素原子が1個から6個であるフェニルアルキル、 (13)アルキレン基の炭素原子が1個から6個であるフェノキシアルキル、 (14)アルキレンの炭素原子が1個から6個であり、R5が (a)水素、および (b)炭素原子1個から6個のアルキルからなるグループか ら選択される−(アルキレン)−N(R5)SO2−フェニル、 (15)アルキレン基の炭素原子が1個から6個である(複素環)オキシアルキ ル、 (16)アルキレン基の炭素原子が1個から6個である−(アルキレン)−S( O)p−複素環、 (17)アルキレン基の炭素原子が1個から6個である−(アルキレン)−複素 環、および (18)アルキレン基の炭素原子が1個から6個である−(アルキレン)−NR6 R7 からなるグループから独立して選択され、 ただし(15)〜(17)において、複素環が (a)ピリジル、 (b)ピラジニル、 (c)ピリダジニル、 (d)フリル、 (e)チエニル、 (f)イソオキサゾリル、 (g)オキサゾリル、 (h)チアゾリル、および (i)イソチアゾリルからなるグループから選択され、 ならびに(10)〜(17)において、フェニル、およびフェニルアルコキシア ルキル、フェニルアルキル、−(アルキレン)−N(R5)SO2−フェニル、フ ェノキシアルキル、−(アルキレン)−S(O)p−フェニルのフェニル部なら びに、複素環、および(複素環)オキシアルキル、−(アルキレン)−複素環、 −(アルキレン)−S(O)p−複素環の複素環部が (a)炭素原子1個から6個のアルキル、 (b)炭素原子1個から6個のアルコキシ、 (c)アルキル基およびアルキレン基の炭素原子が独立して1個から6個である アルコキシアルキル、 (d)ハロ、 (e)炭素原子1個から6個のハロアルキル、 (f)ヒドロキシ、 (g)炭素原子1個から6個のヒドロキシアルキル、 (h)−(アルキレン)−複素環、 (i)−(アルキレン)−フェニル、 (j)−N(R5)SO2−アルキル、 (k)フェニルが (i)シアノ、 (ii)ニトロ、および (iii)ハロ からなるグループから独立して選択される1、2、3、4、または5個の置換基 で任意に置換されているフェニル、 (l)−C(O)OR5、および (m)RxおよびRyが (i)炭素原子1個から6個のアルキル、 (ii)フェニル、および (iii)フェニルアルキル からなるグループから独立して選択され、ただし(ii)および(iii)にお いて、フェニルおよびフェニルアルキルのフェニル部が、ハロおよび炭素原子1 個から6個のアルコキシからなるグループから独立して選択される置換基で任意 に置換されている−C(O)NRxRyからなるグループから独立して選択される 1、2、または3個の置換基で任意に置換され、 ならびに(18)において、R6およびR7が (a)水素、 (b)炭素原子1個から6個のアルキル、 (c)炭素原子3個から8個のシクロアルキル、 (d)シクロアルキル基の炭素原子が3個から8個であり、アルキレン基の炭素 原子が1個から10個であるシクロアルキルアルキル、 (e)炭素原子1個から10個のアルカノイル、 (f)フェニル、および (g)アルキレン基の炭素原子が3個から10個であるフェニルアルキル からなるグループから独立して選択され、 ただし(f)および(g)において、フェニルおよびフェニルアルキルのフェニ ル部が (i)炭素原子1個から6個のアルキル、 (ii)炭素原子1個から6個のアルコキシ、 (iii)炭素原子1個から6個のペルフルオロアルキル、 (iv)ハロ、 (v)炭素原子1個から6個のハロアルキル、および (vi)炭素原子1個から6個のアルカノイル からなるグループから独立して選択される1または2個の置換 基で任意に置換され、あるいは R6およびR7が、それらが結合している窒素原子と共に、 (1)モルホリニル、 (2)チオモルホリニル、 (3)チオモルホリニルスルホン、 (4)ピロリジニル、 (5)ピペラジニル、 (6)ピペリジニル、 (7)スクシンイミジル、 (8)マレイミジル、 (9)グルタルイミジル、 (10)フタルイミジル、 (11)ナフタルイミジル、 からなるグループから選択される基を規定し、 ただし、(1)〜(23)において、それらが結合している窒素原子と共にR6 およびR7によって規定された基が (a)ハロ (b)アルキル (c)アルコキシ (d)フェノキシ (e)フェニルアルキル、および (f)ベンジルオキシ からなるグループから独立して選択される1個または2個の置換基で任意に置換 され、あるいは R1およびR2が、それらが結合している炭素原子と共に、 (1)炭素原子3個から8個のスピロアルキル、および (2)テトラヒドロピラニル からなるグループから選択される環を形成し、あるいは R3およびR4が、それらが結合している炭素原子と共に、炭素原子3個から8個 のスピロアルキル基を形成し、あるいは R1およびR3が、それらが結合している炭素原子と合わせて、5、6、または7 員の炭素環であり、 Xが (1)−O−、 (2)−NR5SO2−、 (3)−S(O)p−、および (4)−C(O)− からなるグループから選択され、 ただし各基は、アルキレン基に結合する末端である左側端、およびAr1に結合 する末端である右側端によって導かれ、 Ar1が (a)炭素原子1個から6個のアルキル、 (b)炭素原子1個から6個のペルフルオロアルキル、 (c)ハロ、 (d)炭素原子1個から6個のハロアルキル、 (e)炭素原子1個から6個のアルコキシ、 (f)ヒドロキシ、 (g)炭素原子1個から6個のヒドロキシアルキル、 (h)アルキルおよびアルキレン基の炭素原子が独立して1個から6個であるア ルコキシアルキル、および (i)ニトロ からなるグループから独立して選択される1または2個の置換基で任意に置換さ れるフェニルであり、 Yが (1)共有結合、 (2)−O−、 (3)炭素原子2個から4個のアルキレン、 (4)ピペリジニル、 (5)炭素原子2個のアルケニレン、 (6)炭素原子2個のアルキニレン、 (7)−S(O)p−、および (8)−C(O)− からなるグループから選択され、ならびに Ar2が (1)フェニル、 (2)ピリジル、 (3)ピラジニル、 (4)ピリダジニル、 (5)フリル、 (6)チエニル、 (7)イソオキサゾリル、 (8)オキサゾリル、 (9)チアゾリル、および (10)イソチアゾリル からなるグループから選択されるアリール基であり、 ただしアリール基が (a)炭素原子1個から6個のアルキル、 (b)炭素原子1個から6個のアルコキシ、 (c)炭素原子1個から6個のアルコキシで置換された炭素原子1個から6個 のアルコキシ、 (d)−アルキル−CO2R5、 (e)−アルキル−NRxRy、 (f)アルキル基の炭素原子が1個から6個であり、アルキレン基の炭素原子 が1個から6個であるアルコキシアルキル、 (g)シアノ、 (h)炭素原子1個から6個のシアノアルキル、 (i)ハロ、 (j)炭素原子1個から6個のハロアルキル、 (k)ヒドロキシ、 (l)炭素原子1個から6個のヒドロキシアルキル、 (m)アルキル基の炭素原子が1個から6個のヒドロキシアルキル、 (n)炭素原子1個から6個のチオアルコキシ、 (o)アルキル基の炭素原子が1個から6個であり、アルキレン基の炭素原子 が1個から6個であるチオアルコキシアルキ ル、 (p)アルキレン基の炭素原子が1個から6個であるフェニルアルコキシ、 (q)フェノキシ、 (r)アルキレン基の炭素原子が1個から6個のフェノキシアルキル、 (s)(複素環)オキシ、 (t)アルキレン基の炭素原子か1個から6個の(複素環)オキシアルキル、 (u)炭素原子1個から6個のペルフルオロアルキル、 (v)ペルフルオロアルキル部の炭素原子が1個から6個のペルフルオロアル コキシ、 (w)アルキル部の炭素原子が1個から6個のスルフィニルアルキル、 (x)アルキル部の炭素原子が1個から6個のスルフォニルアルキル、 (y)Xが−CH2−、−CH2O−、および−O−から選択され、Yが−C( O)−および−(C(R”)2)v−から選択され、ただしR”が水素または炭素 原子1個から4個のアルキ ル、およびvが1〜3である (z)R5が前記定義の通りであり、R5'が (i)水素、および (ii)炭素原子1個から6個のアルキル からなるグループから選択される−N(R5)SO2R5'、および (aa)−SO2N(R5)(R5'・) からなるグループから独立して選択される1、2、または3個の置換基で任意に 置換され、 ただし(s)および(t)において、(複素環)オキシおよび(複素環)オキシ アルキルの複素環部が、 (i)ピリジル、 (ii)ピラジニル、 (iii)ピリダジニル、 (iv)フリル、 (v)チエニル、 (vi)イソオキサゾリル、 (vii)オキサゾリル、 (viii)チアゾリル、および (ix)イソチアゾリル からなるグループから選択され、 ならびに(s)および(t)において、(複素環)オキシおよび(複素環)オキ シアルキルの複素環部が、 (i)炭素原子1個から6個のアルキル、 (ii)炭素原子1個から6個のアルコキシ、 (iii)炭素原子1個から6個のペルフルオロアルキル、 (iv)ハロ、 (v)シアノ、 (vi)シアノアルキル、 (vii)炭素原子1個から6個のハロアルキル、および (viii)炭素原子1個から6個のアルカノイル からなるグループから独立して選択される1または2個の置換基で任意に置換さ れ、 ならびに(q)および(r)において、フェノキシおよびフェノキシアルキルの フェニル部が、 (i)炭素原子1個から6個のアルキル、 (ii)炭素原子1個から6個のアルコキシ、 (iii)炭素原子1個から6個のペルフルオロアルキル、 (iv)ハロ、 (v)シアノ、 (vi)シアノアルキル、 (vii)炭素原子1個から6個のハロアルキル、および (viii)炭素原子1個から6個のアルカノイル からなるグループから独立して選択される1または2個の置換基で任意に置換さ れる化合物または医薬的に許容できるそれらの塩もしくはプロドラッグ。 2.Aが水素、 R1、R3、およびR4が水素または炭素原子1個から6個のアルキルから独立し て選択され、 Xが (1)−O−、 (2)−S(O)p−、および (3)−NR5SO2− からなるグループから選択され、ならびに Ar1が任意に置換されるフェニルである請求の範囲第1項に記載の化合物。 3.R2が炭素原子1個から6個のアルキルである請求の範囲第2項に記載の化 合物。 4.(±)−N−[1−[[[3’−(シアノメチル)−[1,1’−ビフェニ ル]−4−イル]オキシ]メチル]ペンチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−3−メチルブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−メチルブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]ペンチル]−N−ビドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[2−[(4’−シアノ−[1,1’−ビフェニル]−4−イル) オキシ]−1−メチルプロピル]−N−ヒド ロキシホルムアミド、 (±)−N−[1−[[(4’−メトキシ[1,1’−ビフェニル]−4−イル )スルホニル]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−クロロ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(1,3−ベンゾジオキソール−5−イル)フェ ニル]スルホニル]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−クロロフェノキシ)フェニル]スルホニル ]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メトキシ[1,1’−ビフェニル]−4−イル )スルホニル]メチル]プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[1,1−ジメチル−2−[(4’−(トリフルオロメチル )[1,1’−ビフェニル]−4−イル]スルホニル]エチル]−N−ヒドロキ シホルムアミド、および N−[1−[4−[(4−ピリジニルオキシ)フェニル]スルホニル]エチル] −N−ヒドロキシホルムアミド からなるグループから選択される請求の範囲第3項に記載の化合物。 5.R2が水素である請求の範囲第2項に記載の化合物。 6.N−[2−[(4’−シアノ−[1,1’−ビフェニル]−4−イル)オキ シ]エチル]−N−ヒドロキシホルムアミドである請求の範囲第5項に記載の化 合物。 7.R2が (1)フェニル基が置換されていない、または置換されているフェニル、 (2)アルキレン基の炭素原子が1個から6個であり、ならびにフェニル基が置 換されていない、または置換されているフェノキシアルキル、 (3)アルキレン基の炭素原子が1個から6個であり、pがゼロであって、なら びにフェニル基が置換されていない、または置換されている−(アルキレン)− S(O)p−フェニル、 (4)−(アルキレン)−S(O)p−アルキル、 (5)アルキレン基の炭素原子か1個から6個であるヒドロキ シアルキル、 (6)アルキレンの炭素原子が1個から6個であって、フェニル基が置換されて いない、または置換されており、ならびにR5が (a)水素、および (b)炭素原子1個から6個のアルキル からなるグループから選択される−(アルキレン)−N(R5)SO2−フェニル 、 (7)アルキレンおよびアルキル基の炭素原子が独立して1個から6個であり、 ならびにフェニル基が置換されていない、または置換されているフェニルアルコ キシアルキル、 (8)複素環が置換されていない、または置換されている−(アルキレン)−複 素環、 (9)アルキレン基の炭素原子が1個から6個であって、ならびに複素環が置換 されていない、または置換されている(複素環)オキシアルキル、および (10)フェニル基が置換されていない、または置換されている−(アルキレン )−フェニルからなるグループから選択される請求の範囲第2項に記載の化合物 。 8.(±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4− イル)オキシ]メチル]−2−フェノキシエチル]−N−ヒドロキシホルムアミ ド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(フェニルチオ)エチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(4−メチルフェニル)エチル]−N−ヒドロキシホ ルムアミド、 (±)−N−[2−[(4’−シアノ−[1,1’−ビフェニル]−4−イル) オキシ]−1−(4−フルオロフェニル)エチル]−N−ヒドロキシホルムアミ ド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(4−フルオロフェニル)エチル]−N−ヒドロキシ ホルムアミド、 (±)−N−[1−[[(3’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[メチル[(4−メチルフェニル)スルホニル]アミノ ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[[(2−メトキシカルボニル)−フェニル]チオ]エ チル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−5−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −6−イル)オキシ]ペンチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−4−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −6−イル)オキシ]ブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−4−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −7−イル)オキシ]ブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−5−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −7−イル)オキシ]ペン チル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−イソプロピルチオエチル]−N−ヒドロキシホルムアミ ド、 (±)−N−[1−[(フェニルメトキシ)メチル]−2−[[4’−(トリフ ルオロメチル)[1,1’−ビフェニル]−4−イル]スルホニル]エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1−(ヒドロキシメチル)−2−[[(4’−(トリフルオロメ チル)[1,1’−ビフェニル]−4−イル]スルホニル]エチル]−N−ヒド ロキシホルムアミド、 (±)−N−[1−[[(4’−メチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[[3−(メチルスルホニル)−アミノ]フェニル]エ チル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3−(ジエチルアミノ)カルボニル]フェニル]メチ ル]−2−[(4’−メチル[1,1’−ビフェニル]−4−イル)オキシ]エ チル]−N−ヒドロキシホルムアミド、 N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4 −イル)オキシ]メチル]−2−[(4’−シアノ[1,1’−ビフェニル]− 4−イル)オキシ]エチル]−N−ヒドロキシホルムアミド、 N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル)オキシ] メチル]−2−(1,6−ジヒドロ−3−メチル−6−オキソ−1−ピリダジニ ル)エチル]−N−ヒドロキシホルムアミド、および N−[1−[[(4’−シアノ[1,1”−ビフェニル]−4−イル)オキシ] メチル]−2−(1,6−ジヒドロ−6−オキソ−1−ピリダジニル)エチル] −N−ヒドロキシホルムアミド からなるグループから選択される請求の範囲第7項に記載の化合物。 9.R2が−(アルキレン)−NR6R7である請求の範囲第2項に記載の化合物 。 載の化合物。 11.(±)−N−[1−[[(4’−ブトキシ[1,1’− ビフェニル]−4−イル)オキシ]メチル]−2−(4,4−ジメチル−2,5 −ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[(4’−エトキシ[1,1’−ビフェニル]−4−イ ル)オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(1,3−ベンゾジオキソール−5−イル)フェノ キシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’−ビフェ ニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]オキシ]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1 −イミダゾリジニル)プロピル]]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾ リジニル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(メチルスルホニル)[1,1’−ビフェニル ]−4−イル]オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’−ビフェ ニル]−4−イル]チオ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’−ビフェ ニル]−4−イル]スルホニル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−クロロフェノキシ)フェニル]スルホニル ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジニ ル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]オキシ]メチル]−2−(4,4 −ジメチル−2,5−ジオキソ−イミダゾリジニル)エチル]−N−ヒドロキシ ホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(2−メトキシエトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[(4’−プロポキシ[1,1’−ビフェニル]−4− イル)オキシ]エチル]−N−ヒドロキシホルムアミド、 N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジニル) メチル]−2−[(4’−ペンチルオキシ[1,1’−ビフェニル]−4−イル )オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’ −ビフェニル]−4−イル]スルホニル]メチル]−3−(4,4−ジメチル− 2,5−ジオキソ−1−イミダゾリジニル)プロピル]−N−ヒドロキシホルム アミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−フルオロフェノキシ)フェニル]スルホニ ル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジ ニル)エチル]−N−ヒドロキシホルムアミド、 (S)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (R)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル]− 4−イル]オキシ]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1 −イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 N−[1−[4−[(4−ピリジニルチオ)フェノキシ]メチル]−2−(4, 4−ジメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒド ロキシホルムアミド、 N−[1−[[[(4−クロロフェノキシ)フェニル]スルホニル]メチル]− 3−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジニル)プロピル ]−N−ヒドロキシホルムアミド、 N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル]− 4−イル]スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 N−[1−[[[(4−シアノフェノキシ)フェニル]スルホニル]メチル]− 2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル] −N−ヒドロキシホルムアミド、および N−[1−[[4−[[4−(トリフルオロメトキシ)フェノキシ]フェニル] スルホニル]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)プロピル]−N−ヒドロキシホルムアミド からなるグループから選択される請求の範囲第10項に記載の化合物。 12.(±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4 −イル)オキシ]メチル]−2−(2,3−ジヒドロ−1,3−ジオキソ−1H −イソインドール−2−イル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソイミダ ゾリジン−1−イル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−3−(3,4,4−トリメチル−2,5−ジオキソイミダ ゾリジン−1−イル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[4−[(2−E−フェニルエテニル)フ ェノキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(2−フラニル)フェノキシ]メチル]−2−(3 ,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−フルオロ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(3,4,4−トリメチル−2,5−ジオキソ−1−イミ ダゾリジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’− ビフェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メトキシ[1,’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3−メチル−2,5−ジオキソ−1−イミダゾリジ ニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4−(3−チエニル)フェノキシ]メチル]−2−( 3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル] −N−ヒドロキシホルムアミド、 (±)−N−[1−[[([1,1’−ビフェニル]−4−イル)オキシ]メチ ル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニ ル)エチル]−N−ヒドロ キシホルムアミド、 (±)−N−[1−[[(3’−クロロ−4’−フルオロ[1,1’−ビフェニ ル]−4−イル)オキシ]メチル]−2−(3,4,4−トリメチル−2,5− ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(2’−メチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(2,5−ジオキソ−1−イミダゾリジニル)エチル] −N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(1,1−ジオキシド−3−オキソ−1,2−ベンズイ ソチアゾール−2(3H)−イル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(4−フェニル−1−ピペリジニル)フェノキシ] メチル]−2−(3,4,4−トリメチル− 2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[4,4−ジメチル−2,5−ジオキソ−3−(3−ピ リジニルメチル)−1−イミダゾリジニル]エチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(3’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(メチルチオ)[1,1’−ビフェニル]−4 −イル]オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[4−[[4−(トリフルオロメチル)フェノキシ]フェノ キシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(トリフルオロメトキシ)[1, 1’−ビフェニル]−4−イル]オキシ]メチル]−2−(3,4,4−トリメ チル−2,5−ジオキソ−1−イミダゾリジニル)エチル]−2−N−ヒドロキ シホルムアミド、 (±)−N−[1−[[[4’−(メチルスルホニル)[1,1’−ビフェニル ]−4−イル]オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジ オキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)−4’−メトキシ[1,1’ −ビフェニル]−4−イル]オキシ]メチル]−2−(3,4,4−トリメチル −2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルム アミド、 (±)−N−[1−[[(3’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(2,5−ジオキソ−1−ピロリジニル)エチル]−N −ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(4,4−ジメチル−2,6−ジオキソ−1−ピペリジ ニル)エチル]−N−ヒドロキシホルムアミド、 N−[1S−[[(4’−シアノ[1,1’−ビフェニル]− 4−イル)オキシ]メチル]−2−(2,5−ジオキソ−1−ピロリジニル)エ チル]−N−ヒドロキシホルムアミド、 N−[1R−[[(4’−シアノ[1,1’−ビフェニル]−4−イル)オキシ ]メチル]−2−(2,5−ジオキソ−1−ピロリジニル)エチル]−N−ヒド ロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3−エチル−3−メチル−2,5−ジオキソ−1−ピ ロリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(5,5−ジメチル−2,4−ジオキソ−3−オキサゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1 −イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3−メチル−2, 5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド 、 (±)−N−[1−[[(4’−クロロ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−シアノメチル−[1,1’−ビフェニル]−4 −イル)オキシ]メチル]−2−(3,5,5−トリメチル−2,4−ジオキソ −1−イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−シアノメチル−[1,1’−ビフェニル]−4 −イル)オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3−エチル−4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェ ニル]−4−イル)オキシ]メチル]−2−(3−ベンジル−4,4−ジメチル −2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルム アミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,5,5−トリメチル−2,4−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(2,5−ジオキソ−1−イミダゾリジニル)メチル]− 2−[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル]−4−イル ]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(トリフルオロメチル)[1,1’−ビフェニ ル]−4−イル]スルホニル]メチル]−2−(3,4,4−トリメチル−2, 5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド 、 (±)−N−[1−[[(4’−ブチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3−メチル−2,5−ジオキソ−1−イミダゾリジニ ル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(3−メチル−2,5−ジオキソ−1−イミダゾリジニル )メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル ]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−クロロフェノキシ)フェニル]スルホニル ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4−ブチル[1,1’−ビフェニル]−4−イル)ス ルホニル]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[4−(2−チエニル)フェノキシ]メチル]−2−[1− (3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル ]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3−ニトロ[1,1’−ビフェニル]−4−イル)オ キシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N −ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェ ニル]−4−イル]スルホニル]メチル]−2−(3,4,4−トリメチル−2 ,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミ ド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(3−メチル−2,5−ジオキソ−1−イミダゾリ ジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]スルホニル]メチル]−2−(3,4,4−トリメチル−2,5−ジ オキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(4−ピリジニル)フェノキシ]メチル]−2−( 3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル] −N−ヒドロキシホルムアミド、 N−[1−[[[4’−(アミノスルホニル)[1,1’−ビフェニル]−4− イル]オキシ]メチル]−2−(3,4,4 −トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒド ロキシホルムアミド、および N−[1−[[4−[[4−(トリフルオロメトキシ)フェノキシ]フェニル] スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミドからなるグループから選 択される請求の範囲第9項に記載の化合物。 13.R1およびR2が、それらが結合している炭素原子と共に(1)炭素原子3 個から8個のスピロアルキル、および (2)テトラヒドロピラニル から選択される環を形成している請求の範囲第1項に記載の化合物。 14.N−[4−[4−[[(4−クロロフェノキシ)フェニル]スルホニル] メチル]テトラヒドロ−2H−ピラン−4−イル]−N−ヒドロキシホルムアミ ド、および N−[4−[4−[(4’−クロロ[1,1’−ビフェニル]−4−イル)スル ホニル]メチル]テトラヒドロ−2H−ピラン−4−イル]−N−ヒドロキシホ ルムアミド からなるグループから選択される請求の範囲第13項に記載の 化合物。 15.(±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4 −イル)オキシ]メチル]−2−フェノキシエチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(フェニルチオ)エチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(2,3−ジヒドロ−1,3−ジオキソ−1H−イソ インドール−2−イル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソイミダ ゾリジン−1−イル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−3−(3,4,4−トリメチル−2,5−ジオキソイミダ ゾリジン−1−イル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)−[1,1’−ビフェニル] −4−イル]オキシ]メチル]ペンチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−3−メチルブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−メチルブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]ペンチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(4−メチルフェニル)エチル]−N−ヒドロキシホ ルムアミド、 (±)−N−[2−[(4’−シアノ−[1,1’−ビフェニル]−4−イル) オキシ]−1−(4−フルオロフェニル)エチル]−N−ヒドロキシホルムアミ ド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェ ニル]−4−イル)オキシ]メチル]−2−(4−フルオロフェニル)エチル] −N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[2−[(4’−シアノ−[1,1’−ビフェニル]−4−イル) オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[4−[(2E−フェニルエテニル)フェノキシ]メチル] −2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル) エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(2−フラニル)フェノキシ]メチル]−2−(3 ,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル] −N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−フルオロ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(3,4,4−トリメチル−2,5−ジオキソ−1−イミ ダゾリジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’− ビフェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メトキシ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(4,4−ジメチ ル−2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホル ムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[(4’−エトキシ[1,1’−ビフェニル]−4−イ ル)オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(1,3−ベンゾジオキソール−5−イル)フェノ キシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3−メチル−2,5−ジオキソ−1−イミダゾリジ ニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(3−チエニル)フェノキシ]メチル]−2−(3 ,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1−[[([1,1’−ビフェニル]−4−イ ル)オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1 −イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−クロロ−4’−フルオロ[1,1’−ビフェニ ル]−4−イル)オキシ]メチル]−2−(3,4,4−トリメチル−2,5− ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(2’−メチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(2,5−ジオキソ−1−イミダゾリジニル)エチル] −N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(1,1−ジオキシド−3−オキソ−1,2−ベンズイ ソチアゾール−2(3H)−イル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(4−フェニル−1−ピペリジニル)フェノキシ] メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリ ジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’−ビフェ ニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[メチル[(4−メチルフェニル)スルホニル]アミノ ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[4,4−ジメチル−2,5−ジオキソ−3−(3−ピ リジニルメチル)−1−イ ミダゾリジニル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[2−[(4’−シアノ[1,1’−ビフェニル]−4−イル)オ キシ]−1−メチルプロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(メチルチオ)[1,1’−ビフェニル]−4 −イル]オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[4−[[4−(トリフルオロメチル)フェノキシ]フェノ キシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェ ニル]−4−イル]オキシ]メチル]−2−(3,4,4−トリメチル−2,5 −ジオキソ−1−イミダゾリジニ ル)エチル]−2−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(メチルスルホニル)[1,1’−ビフェニル ]−4−イル]オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジ オキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’(シアノメチル)−4’−メトキシ[1,1’− ビフェニル]−4−イル]オキシ]メチル]−2−(3,4,4−トリメチル− 2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]オキシ]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1 −イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−ブトキシ[1,1’−ビフェニル]−4−イル )スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イ ミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−3−(4,4−ジメチル −2,5−ジオキソ−1−イミダゾリジニル)プロピル]−N−ヒドロキシホル ムアミド、 (±)−N−[1−[[[4’−(メチルスルホニル)[1,1’−ビフェニル ]−4−イル]オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(2,5−ジオキソ−1−ピロリジニル)エチル]−N −ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(4,4−ジメチル−2,6−ジオキソ−1−ピペリジ ニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1S−[[(4’−シアノ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(2,5−ジオキソ−1−ピロリジニル)エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1R−[[(4’−シアノ[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(2,5−ジオキ ソ−1−ピロリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3−エチル−3−メチル−2,5−ジオキソ−1−ピ ロリジニル)エチル]−N−ヒドロキシホルムアミド、 N−[4−[4−[[(4−クロロフェノキシ)フェニル]スルホニル]メチル ]テトラヒドロ−2H−ピラン−4−イル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[[(2−メトキシカルボニル)−フェニル]チオ]エ チル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−5−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −6−イル)オキシ]ペンチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−4−[(4−メチル−2 −オキソ−2H−1−ベンゾピラン−6−イル)オキシ]ブチル]−N−ヒドロ キシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−4−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −7−イル)オキシ]ブチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−5−[(4−メチル−2−オキソ−2H−1−ベンゾピラン −7−イル)オキシ]ペンチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(5,5−ジメチル−2,4−ジオキソ−3−オキサゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1 −イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニ ル]−4−イル)オキシ]メチル]−2−(3−メチル−2,5−ジオキソ−1 −イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−クロロ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3’−シアノメチル−[1,1’−ビフェニル]−4 −イル)オキシ]メチル]−2−(3,5,5−トリメチル−2,4−ジオキソ −1−イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−イソプロピルチオエチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(3’−シアノメチル−[1,1’− ビフェニル]−4−イル)オキシ]メチル]−2−(3,4,4−トリメチル− 2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムア ミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3−エチル−4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3−ベンジル−4,4−ジメチル−2,5−ジオキ ソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ−[1,1’−ビフェニル]−4−イル )オキシ]メチル]−2−(3,5,5−トリメチル−2,4−ジオキソ−1− イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メトキシ[1,1’−ビフェニル]−4−イル )スルホニル]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−クロロ[1,1’−ビフェニ ル]−4−イル)スルホニル]メチル]エチル]−N−ヒドロキシホルムアミド 、 (±)−N−[1−[[[4−(1,3−ベンゾジオキソール−5−イル)フェ ニル]スルホニル]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−クロロフェノキシ)フェニル]スルホニル ]メチル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メトキシ[1,1’−ビフェニル]−4−イル )スルホニル]メチル]プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[1,1−ジメチル−2−[(4’−(トリフルオロメチル )[1,1’−ビフェニル]−4−イル]スルホニル]エチル]−N−ヒドロキ シホルムアミド、 (±)−N−[1−[(フェニルメトキシ)メチル]−2−[[4’−(トリフ ルオロメチル)[1,1’−ビフェニル]−4−イル]スルホニル]エチル]− N−ヒドロキシホルムアミド、 (±)−N−[1−(ヒドロキシメチル)−2−[[(4’−(トリフルオロメ チル)[1,1’−ビフェニル]−4−イル] スルホニル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’−ビフェ ニル]−4−イル]チオ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメチル)[1,1’−ビフェ ニル]−4−イル]スルホニル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(2,5−ジオキソ−1−イミダゾリジニル)メチル]− 2−[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル]−4−イル ]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(トリフルオロメチル)[1,1’−ビフェニ ル]−4−イル]スルホニル]メチル]−2−(3,4,4−トリメチル−2, 5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド 、 (±)−N−[1−[[(4’−ブチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(3−メチル−2, 5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド 、 (±)−N−[1−[(3−メチル−2,5−ジオキソ−1−イミダゾリジニル )メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル ]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 N−[4−[4−[(4’−クロロ[1,1’−ビフェニル]−4−イル)スル ホニル]メチル]テトラヒドロ−2H−ピラン−4−イル]−N−ヒドロキシホ ルムアミド、 (±)−N−[1−[[[4−(4−クロロフェノキシ)フェニル]スルホニル ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジニ ル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−クロロフェノキシ)フェニル]スルホニル ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4−ブチル[1,1’−ビフェニル]−4−イル)ス ルホニル]メチル]−2−(3,4,4−トリ メチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシ ホルムアミド、 (±)−N−[1−[[(4’−ブチル[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1 −イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[4−(2−チエニル)フェノキシ]メチル]−2−[1− (3,4,4−トリメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル ]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(3−ニトロ[1,1’−ビフェニル]−4−イル)オ キシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−メチル[1,1’−ビフェニ ル]−4−イル)オキシ]メチル]−2−[[3−(メチルスルホニル)−アミ ノ]フェニル]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3−(ジエチルアミノ)カルボニル]フェニル]メチ ル]−2−[(4’−メチル[1,1’−ビフェニル]−4−イル)オキシ]エ チル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−[(4’−シアノ[1,1’−ビフェニル]−4−イル )オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) オキシ]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾ リジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(2−メトキシエトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[(4’−プロポキシ[1,1’−ビフェニル]−4− イル)オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[(4’−ペンチルオキシ[1,1’−ビフェニル]− 4−イル)オキシ]エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]スルホニル]メチル]−3−(4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェ ニル]−4−イル]スルホニル]メチル]−2−(3,4,4−トリメチル−2 ,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミ ド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(3−メチル−2,5−ジオキソ−1−イミダゾリ ジニル)エチル]−N−ヒ ドロキシホルムアミド、 (±)−N−[1−[[[3’−(シアノメチル)[1,1’−ビフェニル]− 4−イル]スルホニル]メチル]−2−(3,4,4−トリメチル−2,5−ジ オキソ−1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1”−ビフェニル]−4−イル) オキシ]メチル]−2−(1,6−ジヒドロ−3−メチル−6−オキソ−1−ピ リダジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[(4’−シアノ[1,1’−ビフェニル]−4−イル) スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[[4−(4−フルオロフェノキシ)フェニル]スルホニ ル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジ ニル)エチル]−N−ヒドロキシホルムアミド、 (±)−N−[1−[[4−(4−ピリジニル)フェノキシ]メチル]−2−( 3,4,4−トリメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 (S)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 (R)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリ ジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’−ビフ ェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミド、 N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル]− 4−イル]オキシ]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1 −イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 N−[1−[4−[(4−ピリジニルチオ)フェノキシ]メチル]−2−(4, 4−ジメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル]−N−ヒド ロキシホルムアミド、 N−[1−[[[(4−クロロフェノキシ)フェニル]スルホニル]メチル]− 3−(4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、 N−[1−[[(4’−シアノ[1,1”−ビフェニル]−4−イル)オキシ] メチル]−2−(1,6−ジヒドロ−6−オキソ−1−ピリダジニル)エチル] −N−ヒドロキシホルムアミド、 N−[1−[[[4’−(アミノスルホニル)[1,1’−ビフェニル]−4− イル]オキシ]メチル]−2−(3,4,4−トリメチル−2,5−ジオキソ− 1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 N−[1−[[[4’−(トリフルオロメトキシ)[1,1’−ビフェニル]− 4−イル]スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ −1−イミダゾリジニル)エチル]−N−ヒドロキシホルムアミド、 N−[1−[4−[(4−ピリジニルオキシ)フェニル]スルホニル]エチル] −N−ヒドロキシホルムアミド、 N−[1−[[[(4−シアノフェノキシ)フェニル]スルホニル]メチル]− 2−(4,4−ジメチル−2,5−ジオキソ−1−イミダゾリジニル)エチル] −N−ヒドロキシホルムア ミド、 N−[1−[[4−[[4−(トリフルオロメトキシ)フェノキシ]フェニル] スルホニル]メチル]−3−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)プロピル]−N−ヒドロキシホルムアミド、および N−[1−[[4−[[4−(トリフルオロメトキシ)フェノキシ]フェニル] スルホニル]メチル]−2−(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)エチル]−N−ヒドロキシホルムアミド からなるグループから選択される化合物。 16.(S)−N−[1−[(4,4−ジメチル−2,5−ジオキソ−1−イミ ダゾリジニル)メチル]−2−[[4’−(トリフルオロメトキシ)[1,1’ −ビフェニル]−4−イル]オキシ]エチル]−N−ヒドロキシホルムアミドで ある請求の範囲第15項に記載の化合物。 17.そのような治療が必要な哺乳動物においてマトリックスメタロプロテイナ ーゼを阻害する方法であって、治療上有効量の請求の範囲第1項の化合物をその 哺乳動物に投与することを含む方法。 18.医薬担体、および治療上有効量の請求の範囲第1項の化合物を含む、マト リックスメタロプロテイナーゼを阻害するための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90363297A | 1997-07-31 | 1997-07-31 | |
US08/903,632 | 1997-07-31 | ||
PCT/US1998/015486 WO1999006361A2 (en) | 1997-07-31 | 1998-07-27 | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001523272A true JP2001523272A (ja) | 2001-11-20 |
JP3662941B2 JP3662941B2 (ja) | 2005-06-22 |
Family
ID=25417829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51106299A Expired - Fee Related JP3662941B2 (ja) | 1997-07-31 | 1998-07-27 | マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤 |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1001930B1 (ja) |
JP (1) | JP3662941B2 (ja) |
KR (1) | KR100419353B1 (ja) |
CN (1) | CN1178906C (ja) |
AT (1) | ATE228998T1 (ja) |
AU (1) | AU758870B2 (ja) |
BG (1) | BG64307B1 (ja) |
BR (1) | BR9810760A (ja) |
CA (1) | CA2294171C (ja) |
DE (1) | DE69809924T2 (ja) |
DK (1) | DK1001930T3 (ja) |
ES (1) | ES2189207T3 (ja) |
HK (1) | HK1028023A1 (ja) |
HU (1) | HUP0002037A3 (ja) |
IL (1) | IL133369A (ja) |
NO (1) | NO315604B1 (ja) |
NZ (1) | NZ501166A (ja) |
PL (1) | PL337854A1 (ja) |
PT (1) | PT1001930E (ja) |
SK (1) | SK170599A3 (ja) |
TR (1) | TR199903287T2 (ja) |
TW (1) | TW466238B (ja) |
WO (1) | WO1999006361A2 (ja) |
ZA (1) | ZA986828B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002501943A (ja) * | 1998-01-30 | 2002-01-22 | ダーウィン・ディスカバリー・リミテッド | ヒドロキサム酸およびカルボン酸誘導体 |
JP2015044796A (ja) * | 2013-07-31 | 2015-03-12 | 株式会社半導体エネルギー研究所 | シアノビフェニル誘導体、液晶組成物、液晶素子及び液晶表示装置 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
WO2000044712A1 (en) * | 1999-01-27 | 2000-08-03 | Abbott Laboratories | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
US6207701B1 (en) * | 2000-01-28 | 2001-03-27 | Abbott Laboratories | Urokinase inhibitors |
US6350902B2 (en) | 2000-03-31 | 2002-02-26 | Abbott Laboratories | Process for the selective N-formylation of N-hydroxylamines |
US20020019539A1 (en) | 2000-03-31 | 2002-02-14 | Bailey Anne E. | Process for the preparation of matrix metalloproteinase inhibitors |
WO2001074792A2 (en) * | 2000-03-31 | 2001-10-11 | Abbott Laboratories | Process for the preparation of matrix metalloproteinase inhibitors |
AR028075A1 (es) * | 2000-05-05 | 2003-04-23 | Smithkline Beecham Corp | Inhibidores de la peptido-desformilasa |
AR029916A1 (es) | 2000-05-05 | 2003-07-23 | Smithkline Beecham Corp | N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas |
BR0111074A (pt) * | 2000-05-25 | 2003-06-24 | Smithkline Beecham Plc | N-hidroxiformamidas biciclil ou heterobiciclilme-tanossulfonilamino-substituìdos |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SK10932003A3 (sk) * | 2001-03-15 | 2004-04-06 | Astrazeneca Ab | Metaloproteinázové inhibítory |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US7511144B2 (en) | 2001-09-07 | 2009-03-31 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
US20030212056A1 (en) * | 2001-11-02 | 2003-11-13 | Jingwu Duan | Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
GB0128376D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel compounds |
GB0128378D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
TW200831488A (en) | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
ES2599621T3 (es) | 2008-09-04 | 2017-02-02 | Probiodrug Ag | Nuevos inhibidores |
ES2592154T3 (es) | 2010-07-08 | 2016-11-28 | Kaken Pharmaceutical Co., Ltd. | Derivado de N-hidroxiformamida y medicamento que contiene el mismo |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO165341C (no) * | 1985-03-16 | 1991-01-30 | Wellcome Found | Analogifremgangsmaate for fremstilling av terapeutisk aktive hydroksamsyrearylderivater. |
GB9215921D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Anti-inflammatory compounds |
GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
US5665777A (en) * | 1995-11-14 | 1997-09-09 | Abbott Laboratories | Biphenyl hydroxamate inhibitors of matrix metalloproteinases |
-
1998
- 1998-07-27 IL IL13336998A patent/IL133369A/en not_active IP Right Cessation
- 1998-07-27 TR TR1999/03287T patent/TR199903287T2/xx unknown
- 1998-07-27 ES ES98936014T patent/ES2189207T3/es not_active Expired - Lifetime
- 1998-07-27 DE DE69809924T patent/DE69809924T2/de not_active Expired - Fee Related
- 1998-07-27 WO PCT/US1998/015486 patent/WO1999006361A2/en not_active Application Discontinuation
- 1998-07-27 CA CA002294171A patent/CA2294171C/en not_active Expired - Fee Related
- 1998-07-27 BR BR9810760-7A patent/BR9810760A/pt not_active IP Right Cessation
- 1998-07-27 CN CNB988067145A patent/CN1178906C/zh not_active Expired - Fee Related
- 1998-07-27 SK SK1705-99A patent/SK170599A3/sk unknown
- 1998-07-27 AU AU85139/98A patent/AU758870B2/en not_active Ceased
- 1998-07-27 AT AT98936014T patent/ATE228998T1/de not_active IP Right Cessation
- 1998-07-27 HU HU0002037A patent/HUP0002037A3/hu unknown
- 1998-07-27 NZ NZ501166A patent/NZ501166A/en unknown
- 1998-07-27 JP JP51106299A patent/JP3662941B2/ja not_active Expired - Fee Related
- 1998-07-27 PL PL98337854A patent/PL337854A1/xx unknown
- 1998-07-27 EP EP98936014A patent/EP1001930B1/en not_active Expired - Lifetime
- 1998-07-27 PT PT98936014T patent/PT1001930E/pt unknown
- 1998-07-27 KR KR10-1999-7012579A patent/KR100419353B1/ko not_active IP Right Cessation
- 1998-07-27 DK DK98936014T patent/DK1001930T3/da active
- 1998-07-30 ZA ZA986828A patent/ZA986828B/xx unknown
- 1998-10-13 TW TW087112636A patent/TW466238B/zh not_active IP Right Cessation
-
1999
- 1999-12-13 BG BG103995A patent/BG64307B1/bg unknown
- 1999-12-30 NO NO19996579A patent/NO315604B1/no not_active IP Right Cessation
-
2000
- 2000-11-23 HK HK00107516A patent/HK1028023A1/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002501943A (ja) * | 1998-01-30 | 2002-01-22 | ダーウィン・ディスカバリー・リミテッド | ヒドロキサム酸およびカルボン酸誘導体 |
JP2015044796A (ja) * | 2013-07-31 | 2015-03-12 | 株式会社半導体エネルギー研究所 | シアノビフェニル誘導体、液晶組成物、液晶素子及び液晶表示装置 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001523272A (ja) | マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤 | |
US6294573B1 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
US6235786B1 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
US8492582B2 (en) | N-acyl anthranilic acid derivative or salt thereof | |
AU2017200135A1 (en) | Anthelmintic compounds and compositions and method of using thereof | |
PL198503B1 (pl) | Związki pirydazynonowe, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie | |
JP2005536510A (ja) | 抗菌活性を有するn−ヒドロキシアミド誘導体 | |
WO2002018321A2 (en) | Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors | |
US6627767B2 (en) | Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors | |
US20020007060A1 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
BG107908A (bg) | Инхибитори на фарнезилтрансфераза | |
MXPA99011694A (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
EP3515895B1 (en) | Imidazole derivatives for the treatment of hypertension and/or fibrosis | |
JP4788860B2 (ja) | イミダゾール化合物およびそのアデノシンデアミナーゼ阻害剤としての使用 | |
CZ473099A3 (cs) | Reversní hydroxamátové inhibitory matrixových metalloproteinás | |
WO2000044712A1 (en) | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | |
JP2005537216A (ja) | セリンおよびシステインプロテアーゼの阻害剤としてのプロピルカーバメート誘導体 | |
MXPA01007658A (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
JP2005504098A (ja) | 過剰増殖性障害の処置に有用なピラゾール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050325 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080401 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090401 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100401 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100401 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110401 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |